Creo Medical Group (LON:CREO) Sets New 12-Month Low – Should You Sell?

Creo Medical Group PLC (LON:CREO)’s stock price hit a new 52-week low on Monday . The stock traded as low as GBX 14.25 ($0.18) and last traded at GBX 14.50 ($0.19), with a volume of 364450 shares. The stock had previously closed at GBX 14.55 ($0.19).

Creo Medical Group Stock Performance

The business’s fifty day moving average is GBX 18.66 and its 200-day moving average is GBX 26.89. The company has a quick ratio of 2.19, a current ratio of 3.24 and a debt-to-equity ratio of 29.96. The company has a market cap of £50.65 million, a PE ratio of -237.50 and a beta of 0.86.

Insider Buying and Selling

In other Creo Medical Group news, insider Richard John Rees bought 98,000 shares of the business’s stock in a transaction that occurred on Thursday, October 24th. The stock was purchased at an average price of GBX 20 ($0.26) per share, for a total transaction of £19,600 ($25,041.52). Also, insider Kevin Crofton purchased 2,916,666 shares of the stock in a transaction that occurred on Monday, October 21st. The stock was acquired at an average cost of GBX 24 ($0.31) per share, for a total transaction of £699,999.84 ($894,339.90). 22.43% of the stock is owned by insiders.

Creo Medical Group Company Profile

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.